Abstract
Inhibitors of angiotensin converting enzyme (ACE-Is) and angiotensin (ANG) receptor antagonists were originally developed to aid in the management of hypertension. As the use of these agents was extended to the management of heart failure and other cardiovascular diseases, studies of tissue remodeling suggested that blockade of ANGII function might play a role in the regulation of cell death by apoptosis. Experiments with cultured cells confirmed that ANGII is an inducer of apoptosis in well differentiated cell types isolated from the heart, kidneys, lungs and other organs. More recent evidence with animal models strongly suggests that ACE-Is and ANG receptor antagonists, in addition to affecting hemodynamics, also influence disease progression through direct inhibition of ANG-induced apoptosis. This manuscript reviews the evidence supporting this view, discusses its potential relevance to disease pathogenesis and offers new hypotheses regarding novel uses of ACE-Is and ANG receptor antagonists in the control of cell death.
Keywords: Apoptosis, Angiotensin Receptor, cardiovascular diseases, ACE-Is, hypertension
Current Pharmaceutical Design
Title: Blockade of Apoptosis by ACE Inhibitors and Angiotensin Receptor Antagonists
Volume: 9 Issue: 9
Author(s): Gerasimos Filippatos and Bruce D. Uhal
Affiliation:
Keywords: Apoptosis, Angiotensin Receptor, cardiovascular diseases, ACE-Is, hypertension
Abstract: Inhibitors of angiotensin converting enzyme (ACE-Is) and angiotensin (ANG) receptor antagonists were originally developed to aid in the management of hypertension. As the use of these agents was extended to the management of heart failure and other cardiovascular diseases, studies of tissue remodeling suggested that blockade of ANGII function might play a role in the regulation of cell death by apoptosis. Experiments with cultured cells confirmed that ANGII is an inducer of apoptosis in well differentiated cell types isolated from the heart, kidneys, lungs and other organs. More recent evidence with animal models strongly suggests that ACE-Is and ANG receptor antagonists, in addition to affecting hemodynamics, also influence disease progression through direct inhibition of ANG-induced apoptosis. This manuscript reviews the evidence supporting this view, discusses its potential relevance to disease pathogenesis and offers new hypotheses regarding novel uses of ACE-Is and ANG receptor antagonists in the control of cell death.
Export Options
About this article
Cite this article as:
Filippatos Gerasimos and Uhal D. Bruce, Blockade of Apoptosis by ACE Inhibitors and Angiotensin Receptor Antagonists, Current Pharmaceutical Design 2003; 9 (9) . https://dx.doi.org/10.2174/1381612033455477
DOI https://dx.doi.org/10.2174/1381612033455477 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors
Current Medicinal Chemistry Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Left Ventricular Hypertrophy: A Shift in Paradigm
Current Medicinal Chemistry The Role of Adipokines in Hypertension and Cardiovascular Disease
Current Hypertension Reviews Protein Pool Maintenance During Oxidative Stress
Current Pharmaceutical Design MicroR-26b Targets High Mobility Group, AT-hook 2 to Ameliorate Myocardial Infarction-induced Fibrosis by Suppression of Cardiac Fibroblasts Activation
Current Neurovascular Research Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Anti-Cancer Agents in Medicinal Chemistry (Pro)renin Receptor as a New Drug Target
Current Pharmaceutical Design A Comprehensive and Contemporary Review on Immunosuppression Therapy for Heart Transplantation
Current Pharmaceutical Design Sleep Disturbances in Cystic Fibrosis
Current Respiratory Medicine Reviews Biomarkers Associated with Atrial Fibrosis and Remodeling
Current Medicinal Chemistry N-Acetylcysteine and Other Preventive Measures for Contrast-Induced Nephropathy in the Intensive Care Unit
Current Medicinal Chemistry The Prodigiosins: A New Family of Anticancer Drugs
Current Cancer Drug Targets Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Selective Glucocorticoid Receptor Ligands
Medicinal Chemistry Psoriatic Arthritis and its Novel Therapeutics
Current Rheumatology Reviews Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design CD26 Inhibition Enhances Perfusion Recovery in ApoE-/-Mice
Current Vascular Pharmacology Endothelins Role in the Control of the Acute Phase of Trypanosoma cruzi Infection
Mini-Reviews in Medicinal Chemistry